Skip to main content

Azora Therapeutics, Inc.

corporate_fare Company Profile

Azora Therapeutics, Inc.

AZR·NASDAQ·Life Sciences·CIK 0001513525

Azora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder ("AUD"). AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using the company's companion diagnostic genetic test. Based on its analysis of the subgroup data from the ONWARD trial, Azora Therapeutics is now focused on completing the clinical development program for AD04 in the specified genetic subgroups to meet regulatory requirements primarily in the US and secondarily in Europe/UK. The company has devoted the vast majority of its resources to development efforts relating to AD04, including preparation for and conducting clinical trials, providing general and administrative support for these operations and protecting its intellectual property, and expects these activities to continue to demand most of its resources for the foreseeable future. Azora Therapeutics currently does not have any products approved for sale and has not generated any significant revenue since its inception. From its inception through the date of filing its Annual Report on Form 10-K, the company has funded its operations primarily through the private and public placements of debt, equity securities, and an equity line. Its current cash and cash equivalents are not expected to be sufficient to fund operations for the twelve months from the date of filing the Annual Report on Form 10-K, based on its current commitments and development plans. Azora Therapeutics has incurred net losses in each year since its inception, including net losses of approximately $8.0 million and $13.2 million for the years ended December 31, 2025 and 2024, respectively. It had accumulated deficits of approximately $90.0 million and $82.0 million as of December 31, 2025 and 2024, respectively.

Azora Therapeutics, Inc. (NASDAQ:AZR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for AZR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for AZR spans S-3.

Recent high-impact activity:

  • Azora Files $250M Shelf and $20M Jefferies ATM, Replacing A.G.P. Program
  • Q3 Loss Widens to $64.6M on $57.1M Non-Cash Warrant Charge; Cash Falls to $22M

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$7.98M
Diluted EPS
-$11.93
Op. Cash Flow
-$6.49M
Operating Income
-$7.8M
Cash & Equivalents
$5.88M
Debt / Equity
0.00×
Shares Outstanding
1.11M sh
Source: 10-K · filed 2026-03-05 · accession 0001213900-26-024175

Short Interest & Short Volume

4.13 days to cover

FINRA reported short interest of 217,174 shares in AZR as of the October 30, 2026 settlement, a 20.9% increase from the prior period — about 4.1 days to cover at its recent average daily volume. On November 20, 2026, 4.6% of AZR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)217,174 shares as of October 30, 2026
Change vs prior period▲ 20.9%
Days to cover4.13 at avg daily volume of 52,562
Daily short volume (FINRA facilities)4.6% of 31,137 shares on November 20, 2026
5-day average short volume5.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AZR, detected from its recent SEC filings.

2 shelf registrations

New $250M Shelf and $20M ATM · Prior ATM Terminated

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

$3.77 -2.08% today
52-week range · as of 2026-11-17 $1.31 – $8.25
Market cap
$55M
Volume
42.8K (0.8× avg)
3-mo avg 54.6K
Live data · 2026-11-22 05:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AZR - Latest Insights

AZR
Nov 16, 2026, 9:45 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $3.81
Real-time Price: $3.77 info
Change: -$0.040 (-1%) info
Market Cap: $55.002M info
AZR
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.74
Real-time Price: $3.77 info
Change: +$0.030 (+0.80%) info
Market Cap: $55.002M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets